<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00672607</url>
  </required_header>
  <id_info>
    <org_study_id>Schwabe-Wenex</org_study_id>
    <nct_id>NCT00672607</nct_id>
  </id_info>
  <brief_title>a Clinical Trial to Evaluate the Efficacy and Safety of Agnucaston Tablets in the Treatment of Premenstrual Syndrome (PMS)</brief_title>
  <acronym>ACT-RCT-C 01</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Schwabe-Wenex International Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Schwabe-Wenex International Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy and safety of Agnucaston tablets with placebo for the treatment of
      Premenstrual Syndrome (PMS) and assess if Agnucaston tablets are superior to placebo on
      efficacy or not.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Premenstrual syndrome (PMS) is a common disorder in women and consists of somatic and/or
      behavioral/mood symptoms, which can impair a woman's social and work-related functioning.
      Some clinical studies with preparations containing Vitex agnus castus have demonstrated a
      positive effect on PMS with good tolerability. The aim of this clinical trial is to
      investigate the efficacy and safety of Agnucaston tablets for the therapy of PMS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline (cycle 0) of premenstrual complaints, assessed by the sum score of the 18 items of the PMS-Diary, after 3 cycles under treatment, evaluated for the luteal phase, i.e. the last 7 days prior a menstrual bleeding.</measure>
    <time_frame>the last 7 days prior a menstrual bleeding</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (cycle 0) of the sum score of the 36 questions of the PMTS self-assessment scale after 3 cycles under treatment.</measure>
    <time_frame>on the 1st-3nd day of menstrual bleeding</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">217</enrollment>
  <condition>Premenstrual Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>extracts of Vitex agnus castus tablets</intervention_name>
    <description>orally, one tablet daily. Apply for a period of 3 months. Do not interrupt during menses period.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Agnucaston tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of PMS disease

          -  Age between 18 and 45 years

          -  Patients is in general good health

        Exclusion Criteria:

          -  Any of the following endocrinological diseases: diabetes mellitus,
             hypo-/hyperthyreosis, pituitary tumor.

          -  Clearly kidney or liver disease, abnormal kidney or liver function.

          -  Any of the following gynecological diseases: endometriosis, mammary carcinoma,
             intraductal papilloma, galactorrhea, mammary fibroadenoma.

          -  Prior to the start of the study any planned surgical intervention of the breasts
             (including cyst puncture), of the uterus and/ or adnexa.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2008</study_first_submitted>
  <study_first_submitted_qc>May 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2008</study_first_posted>
  <last_update_submitted>September 30, 2009</last_update_submitted>
  <last_update_submitted_qc>September 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>Helen Guo</name_title>
    <organization>Schwabe-Wenex</organization>
  </responsible_party>
  <keyword>premenstual syndrome, PMS, clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Premenstrual Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

